Daxxin Psoriasis Shampoo PMCF

Launched by DAXXIN AB · Jan 7, 2025

Keywords

ClinConnect Summary

The Daxxin Psoriasis Shampoo clinical trial is studying the effectiveness and safety of a specially designed shampoo for treating scalp psoriasis, a skin condition that can cause redness, irritation, and flaking. The trial will involve 41 adults aged 18 and older who have moderate scalp psoriasis, defined by specific symptoms. Participants will need to use the shampoo between 3 and 7 times a week for six weeks and attend follow-up visits to monitor their progress.

To be eligible for this trial, individuals must be diagnosed with moderate scalp psoriasis and willing to follow the study instructions, which include not using other psoriasis treatments during the study. Important criteria for exclusion include having allergies to the shampoo's ingredients, recent use of other psoriasis treatments, or any condition that could affect participation. This trial is not yet recruiting participants, but it offers a chance for those affected by scalp psoriasis to potentially find a new treatment option while contributing to important research.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Male or female ≥18 years old
• • 2. Clinical diagnosis of moderate scalp psoriasis assessed by Psoriasis Scalp Severity Index (PSSI, moderate = 3-10)
• • 3. At least a score of 1 grade for each symptom erythema, induration and desquamation
• • 4. Subject is willing and able to use Daxxin Psoriasis Shampoo as directed, comply with investigation instructions, and commit to all follow-up visits for the duration of the investigation, as judged by the Investigator
• • 5. Subject agrees to refrain from using other treatments for scalp psoriasis during the clinical investigation
• • 6. Subject is willing and able to provide written informed consent
• Exclusion Criteria:
• • 1. Known allergy or sensitivity to any component of the device
• • 2. Use of psoriasis shampoo 2 weeks prior to enrolment
• • 3. Use of other psoriasis scalp treatment i.e., Betnovate that could affect the study result within 4 weeks prior to enrolment
• • 4. Use of systemic and/or biological treatment for psoriasis
• • 5. Subject has a history of psoriasis unresponsive to topical treatments
• • 6. Subject is pregnant, lactating at time of enrolment, or is planning to become pregnant during the study
• • 7. Subjects with any other condition that, as judged by the investigator, may make investigation procedures inappropriate
• • 8. Subject with alcohol or drug abuse